

Contents

Prologue — VI

1 Acetylcholine — 1

- 1.1 Goals — 1
- 1.2 Nerve transmission through the synapse — 1
- 1.3 Cholinergic nervous system: muscarinic and nicotinic receptors — 3
- 1.4 Direct agonist drugs — 6
- 1.5 Molecular modifications of AcC — 6
 - 1.5.1 Modifications in the ammonium moiety — 7
 - 1.5.2 Modifications of the ethylenic bridge — 7
 - 1.5.3 Modifications of the acyloxy group — 8
- 1.6 Synthesis of methacholine and bethanechol — 11
- 1.7 Muscarinic drugs derived from other models — 11
- 1.8 Clinical uses of cholinergic agonists — 12
 - 1.8.1 Muscarinic agonists — 12
 - 1.8.2 Nicotinic agonists — 12
- 1.9 Muscarinic antagonists. Clinical effects — 12
 - 1.9.1 Clinical uses — 12
- 1.10 Muscarinic antagonists — 12
 - 1.10.1 Atropine — 12
 - 1.10.2 Hyoscine — 13
- 1.11 Structural analogues based on atropine — 14
- 1.12 Main anticholinergic drugs obtained by synthesis. Structure-activity relationships — 15
- 1.13 M2 Antimuscarinics — 16
- 1.14 Antagonist drugs on nicotinic receptors — 16
 - 1.14.1 Decamethonium and suxamethonium — 19
 - 1.14.2 Atracurium — 19
- 1.15 Anticholinesterases and acetylcholinesterase — 21
 - 1.15.1 Effect of anticholinesterases — 21
 - 1.15.2 Acetylcholinesterase active center — 21
 - 1.15.3 Anticholinesterase drugs — 22

2 Noradrenaline — 30

- 2.1 Goals — 30
- 2.2 Introduction — 30
- 2.3 Adrenergic synapses — 30
- 2.4 Drugs that focus on the noradrenaline biosynthesis. False transmitters — 31
- 2.5 Drugs that affect the release of stored noradrenaline — 33

- 2.6 Mechanism of action of the MAOs — 35
- 2.7 Adrenergic indirect drugs — 36
- 2.8 Catechol-*O*-methyltransferase inhibitors (COMT) — 40
- 2.9 Direct adrenergic (postsynaptic agonists) drugs — 40
- 2.10 Adrenergic β -blockers — 46
- 2.10.1 Regioselective opening of epoxides in basic media — 48
- 2.10.2 Regioselective opening of epoxides in acidic media — 48
- 2.11 α -Adrenergic blockers — 52
- 2.11.1 Competitive antagonists of the NA and A — 52
- 2.11.2 Noncompetitive antagonists of NA, especially β -haloethylamines, capable of irreversibly alkylating the receptor — 52
- 2.11.3 Benzodioxanes and other synthetic heterocycles. Imidazolines — 53

3 Dopamine — 55

- 3.1 Goals — 55
- 3.2 Introduction: Antiparkinsonians related to the action or release of dopamine — 55
- 3.2.1 Conformationally restricted analogues of dopamine — 56
- 3.3 Direct agonists — 57
- 3.4 MAO and COMT inhibitors — 59
- 3.5 Drugs capable of causing the release of dopamine from the peripheral neural sites at the presynaptic level — 61
- 3.6 Other dopaminergic agonists — 61
- 3.7 Dopaminergic antagonists — 63
- 3.7.1 Tricyclic neuroleptics: Phenothiazines and thioxanthenes — 64
- 3.7.2 Butyrophenones and analogues — 69
- 3.7.3 *ortho*-Methoxybenzamides (orthopramides) — 72

4 Serotonin and reuptake inhibitors of biogenic amines — 74

- 4.1 Goals — 74
- 4.2 Introduction — 74
- 4.3 Reuptake inhibitors: Tricyclic antidepressants — 74
- 4.4 MAO inhibitors (MAOI) — 76
- 4.5 Serotonin — 77
- 4.6 Selective serotonin reuptake inhibitors (SSRIs) — 79
- 4.7 Direct action on serotonergic receptors — 79
- 4.7.1 5-HT_{1D} Agonists. Antimigraine drugs — 79
- 4.7.2 5-HT_{1A} Agonists — 82
- 4.7.3 5-HT₃ Antagonists — 82
- 4.8 Summary — 86

5 Amino acids as neurotransmitters — 88

- 5.1 Goals — 88

- 5.2 Introduction — **88**
- 5.3 Inhibitors of γ -aminobutyric acid (GABA) — **88**
- 5.4 Presynaptic modulators — **89**
- 5.5 Enzymic inhibitors that have pyridoxal phosphate as cofactor — **90**
- 5.6 Postsynaptic modulators — **93**
- 5.6.1 Benzodiazepines — **94**
- 5.6.2 Fixation of steroids to GABA_A — **102**
- 5.6.3 Other drugs related to benzodiazepines — **102**
- 5.6.4 Barbituric acids (or barbiturates) — **102**

6 Peptides as neurotransmitters: Hypnoanalgesics — 106

- 6.1 Goals — **106**
- 6.2 Morphine — **106**
- 6.2.1 SARs — **107**
- 6.2.2 Development of morphine analogues: Strategies — **110**
- 6.2.3 Multiple analgesic receptors — **123**
- 6.2.4 Agonists and antagonists — **124**
- 6.2.5 Enkephalins and endorphins — **126**
- 6.2.6 Enkephalin analogues — **127**

7 Histamine and antihistaminics — 128

- 7.1 Goals — **128**
- 7.2 Histamine — **128**
- 7.2.1 H₁ Antihistaminics: synthesis and SARs — **130**
- 7.2.2 Second-generation H₁ antihistaminics — **134**
- 7.3 Cimetidine: Example of a rational approach in the design of a drug — **137**
- 7.3.1 Beginnings: ulcer therapy in 1964 — **139**
- 7.3.2 Two histaminic receptors — **140**
- 7.3.3 Looking for a leader: histamine — **140**
- 7.4 Searching for a leader: N^α-Guanylhistamine — **141**
- 7.5 The theory of chelation — **144**
- 7.6 From a partial agonist to an antagonist: Development of burimamide — **146**
- 7.7 Development of methiamide — **146**
- 7.8 Cimetidine development — **149**
- 7.8.1 Cimetidine metabolism — **151**
- 7.8.2 Cimetidine synthesis — **152**
- 7.8.3 Conformational isomers of cimetidine — **153**
- 7.8.4 Desolvation — **154**
- 7.8.5 Development of the ketenaminal (or diaminonitroethylene) group — **155**
- 7.9 Cimetidine development — **159**

7.10	Summary of cimetidine design —	160
7.11	Comparison between H ₁ and H ₂ antagonists —	160
8	Enzymatic inhibitors I —	162
8.1	Goals —	162
8.2	Introduction —	162
8.3	Carbonic anhydrase (CA) inhibitors —	162
8.4	Renin-angiotensin pathway —	165
8.4.1	Angiotensin II antagonists. X-ray crystallographic studies —	167
9	Enzymatic inhibitors II —	172
9.1	Goals —	172
9.2	Introduction —	172
9.3	Classification of nonsteroidal anti-inflammatory drugs (NSAIDs) —	175
9.3.1	Arylacetic acids or “fenacs” —	176
9.3.2	Arylpropionic acids or “profens” —	178
9.3.3	Naproxen —	179
9.3.4	N-Arylanthranilic (fenamic) acids —	180
9.3.5	Enols (oxicams) —	181
9.3.6	COX-2 selective inhibitors: Coxibs —	182
10	Design of drugs acting on transport through biological membranes —	184
10.1	Goals —	184
10.2	Design of drugs that act on transport through cell membranes —	184
10.3	Voltage-gated sodium channels —	184
10.3.1	Local anesthetics —	187
10.4	Voltage-dependent calcium channels —	191
10.4.1	Calcium channel blockers: Structural families —	191
10.4.2	H ⁺ /K ⁺ -ATPase inhibitors: Antiulcer drugs —	193
11	Enzymatic inhibition: Inhibitors of the biosynthesis of the cellular wall —	196
11.1	Goals —	196
11.2	Antibiotics —	196
11.3	Penicillins —	196
11.3.1	Structure of penicillins —	197
11.3.2	Various penicillins —	197
11.3.3	Properties of penicillin G —	198
11.3.4	Structure-activity relationships of penicillins —	199
11.3.5	Sensitivity of penicillin G to acids —	199
11.3.6	Penicillins sensitive to β-lactamases —	202
11.3.7	Facing the problem of β-lactamase sensitivity —	203
11.3.8	Resistance to penicillins —	204

- 11.3.9 Addressing the narrow-spectrum problem — 206
- 11.4 Cephalosporins — 208
- 11.4.1 SARs of cephalosporin C — 210
- 11.4.2 Cephalosporin C analogues by variation of the 7-acylamine side chain — 211
- 11.4.3 Cephalosporin C analogues by variation of the 3-acetoxymethyl side chain — 212
- 11.4.4 Synthesis of 3-methylated cephalosporins — 213
- 11.4.5 Disclaimer — 214
- 11.4.6 Summary of the properties of cephalosporins — 214
- 11.5 Clavulanic acid (Beechams, 1976) — 215
- 11.6 Mechanism of action of penicillins and cephalosporins — 217

12 Enzymatic inhibition: Other antibacterial agents — 221

- 12.1 Goals — 221
- 12.2 Introduction — 221
- 12.3 SARs — 222
- 12.4 Sulfanilamide analogues — 222
- 12.5 Applications of sulfonamides — 223
- 12.6 Mechanism of action — 224
- 12.7 Synthesis of sulfonamides — 226
- 12.8 Examples of other antimetabolites — 226
- 12.8.1 Trimethoprim — 227
- 12.9 Antibacterial agents affecting protein synthesis — 228
- 12.9.1 Rifamycins — 229
- 12.9.2 Aminoglycosides — 229
- 12.9.3 Tetracyclines — 230
- 12.9.4 Chloramphenicol — 230
- 12.9.5 Erythromycin — 232
- 12.9.6 Aminoacridines — 232
- 12.9.7 1,8-Naphthyridine and fluoroquinolones — 234

13 Enzymatic inhibition: Inhibitors of biosynthesis of nitrogenated bases — 238

- 13.1 Goals — 238
- 13.2 Introduction — 238
- 13.3 Nucleic acids — 238
- 13.4 Thymidylate synthase inhibitors — 238
- 13.4.1 Tetrahydrofolic acid — 240
- 13.4.2 5-Fluorouracil (5-FU) — 241
- 13.5 DHFR inhibitors — 245
- 13.6 Tyrosine kinase inhibitors — 245
- 13.6.1 Structure of tyrosine kinase receptors — 248

13.6.2	Mechanisms of activation of the EGF receptor tyrosine kinase —	248
13.6.3	Example of a kinase inhibitor for clinical use (gefitinib) —	249
13.7	Antivirals —	252
13.7.1	Antiviral inhibitors of DNA polymerases and other enzymes —	252

Index —	257
---------	-----